Skip to content
Open access

The DCBLD2 super-enhancer drives colorectal cancer progression through FOSL2/JUND-mediated activation of the CD146/AKT/TNFRSF6B pathway

Sep 2026 · Molecular Biomedicine · Vol 7 · 0 citations · 44 references
Medicine

TL;DR

This study uncovers a previously undescribed DCBLD2-centered regulatory cascade that promotes colorectal cancer initiation and progression and represents promising prognostic biomarkers and actionable therapeutic targets for colorectal cancer.

Abstract

Super-enhancers are clusters of cis-regulatory elements that sustain the expression of cell-identity genes. Their aberrant activation or dysfunction constitutes a hallmark of malignant cellular transformation, which frequently rewires oncogenic transcriptional programs to support uncontrolled cell proliferation and metastatic potential. However, the functions and epigenetic regulation mechanisms of colorectal cancer specific super-enhancers remain poorly understood, and few studies have focused on dissecting how tumor enriched super-enhancers mediate downstream oncogenic signaling in CRC. By integrating multi-omics sequencing data, we identified a highly active super-enhancer in colorectal cancer, termed DCBLD2-SE. Through luciferase reporter assays, the SE3-2 subregion was identified as the minimal functional core of this super-enhancer. Mechanistic studies confirmed that transcription factors of the activator protein-1 family (FOSL2 and JUND) can bind directly to the SE3-2 cis-regulatory element, synergistically regulating local chromatin remodeling and strongly driving the upregulation of the target gene DCBLD2. Following knockout of the DCBLD2-SE core region, the malignant proliferative capacity of colorectal cancer cells decreased significantly, and the growth of xenograft tumors in vivo was markedly inhibited. Functionally, DCBLD2-SE facilitates tumor progression through a DCBLD2-dependent CD146/AKT/TNFRSF6B signaling axis. Clinically, high expression of DCBLD2 correlates with malignant metastasis and poor overall survival in patients with colorectal cancer. In summary, this study uncovers a previously undescribed DCBLD2-centered regulatory cascade that promotes colorectal cancer initiation and progression. DCBLD2-SE and its binding transcription factor activator protein-1 represent promising prognostic biomarkers and actionable therapeutic targets for colorectal cancer.

Read PDF

Similar papers

Open access Sep 2026

A core transcriptional regulatory circuitry controls super-enhancer-driven activation of LGR5 in colorectal cancer

The core transcriptional regulatory program governed by a small set of master transcription factors is pivotal for establishing context-specific cellular features. Here, we report the roles of master factor MYC in actively regulating cancer-type specific super-enhancer activity and orchestrating a super-enhancer-depend...

Min Ye, Shi-Lan Wang, Yong-Heng Chen et al. · 0 citations
Open access Sep 2026

ZEB1 directly activates IL-6 to promote triple-negative breast cancer stemness in an epigenetically constrained context

The findings establish the ZEB1–IL-6 axis as an important regulator of triple-negative breast cancer (TNBC) stemness and indicate that ZEB1-dependent IL-6 activation is influenced by the local epigenetic context, which supports further investigation of the ZEB1-high TNBC.

Wei-Yue Zhang, Yifan Zhou, Wei Ma et al. · 0 citations
Open access Sep 2026

A prostate cancer-specific super-enhancer at 1q42.3 regulates the CAPN2 and KRT19.

The findings provide insights into a functional epigenetic element within a classic genetic risk locus, proposing a mechanism by which super-enhancer-mediated regulation promotes prostate cancer progression.

Zhen-Hao Zhao, Yun-Long Bai, Qin Wang et al. · 0 citations
Open access Sep 2026

The H19/miR-760/BST2 regulatory axis sustains breast cancer tumorigenesis and metastasis.

The long noncoding RNA H19 has been widely attested as a promoter of breast cancer by favoring proliferation, migration, invasion, and tumor growth. In this study, we attempted to decipher molecular mechanisms underlying oncogenic activities of H19. Transcriptomic analyses revealed that H19 overexpression correlates wi...

Kekely Klouyovo, Evodie Peperstraete, Léa Mabille et al. · 0 citations
Review Open access Sep 2026

MED1 in cancer: a context-dependent transcriptional regulator

An evidence-weighted, locus- and complex-centered framework to reconcile the MED1 paradox is advanced and it is proposed that MED1 output is determined by lineage-specific transcription-factor recruitment, genomic occupancy, signaling-dependent modification, chromatin state, and cellular context.

Zhe Li, Zhaosong Meng, Lei Sui et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.